The antimycobacterial drugs market is projected to grow from USD 4,200 million in 2025 to USD 5,924.5 million by 2035, at a CAGR of 3.5%. By product type, first-line TB drugs will lead with a 40.5% market share, while by application, pulmonary TB will dominate with a 62% share in 2025.